Similar articles

• Chronic allograft nephropathy.

  Ponticelli C. Ponticelli C. N Engl J Med. 2004 Mar 18;350(12):1254-6; author reply 1254-6. doi: 10.1056/NEJM200403183501216. N Engl J Med. 2004. PMID: 15028831 No abstract available.
• Chronic allograft nephropathy.

  Najafian B, Kasiske BL. Najafian B, et al. Curr Opin Nephrol Hypertens. 2008 Mar;17(2):149-55. doi: 10.1097/MNH.0b013e3282f4e514. Curr Opin Nephrol Hypertens. 2008. PMID: 18277147 Review.
• Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?

  Wali RK, Weir MR. Wali RK, et al. Curr Opin Organ Transplant. 2008 Dec;13(6):614-21. doi: 10.1097/MOT.0b013e3283193bad. Curr Opin Organ Transplant. 2008. PMID: 19060552 Review.
• Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.

  Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C. Falger JC, et al. Pediatr Transplant. 2006 Jun;10(4):474-8. doi: 10.1111/j.1399-3046.2006.00503.x. Pediatr Transplant. 2006. PMID: 16712606
• Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.

  Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L. Bumbea V, et al. Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. doi: 10.1093/ndt/gfh957. Epub 2005 Jun 28. Nephrol Dial Transplant. 2005. PMID: 15985508